Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Ruijin Hospital
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07638787CT.gov Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL | — | Not Yet Recruiting | — | — | — |
NCT07608731CT.gov Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas | — | Not Yet Recruiting | — | — | — |
NCT07594899CT.gov AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | — | Not Yet Recruiting | — | — | — |
NCT06919939CT.gov Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT07269639CT.gov Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07215585CT.gov AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL | — | Recruiting | — | — | — |
NCT06167785CT.gov A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T | — | Recruiting | — | — | — |
NCT06564038CT.gov A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | — | Recruiting | — | — | — |
NCT06674096CT.gov RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL | — | Recruiting | — | — | — |
NCT06356129CT.gov Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
Show 8 more trialsShow fewer
NCT06375733CT.gov A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | — | Recruiting | — | — | — |
NCT06045247CT.gov Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05929716CT.gov An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | — | Withdrawn | — | — | — |
NCT06047080CT.gov An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05820841CT.gov Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT05600686CT.gov Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT03984448CT.gov Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05733650CT.gov Expanded Access Program for Epcoritamab | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | Ruijin Hospital | P3 | B · 63 |
| Axicabtagene Ciloleucel | Zhejiang Cancer Hospital | P4 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Fludarabine | M.D. Anderson Cancer Center | P4 | BB |
| Etoposide | University of California, Davis | P2/3 | BB |
| Adriamycin | Ruijin Hospital | P3 | BB |
| Prednisone | Ruijin Hospital | P3 | BB |
| Golcadomide | Allison Winter | P3 | B |
| Lenalidomide | Ruijin Hospital | P3 | B |
+41 more in the Large B-Cell Lymphoma cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →